In fact, compounds blocking DOT1L activity or impairing binding between KMT2A-AF4 aberrant protein and its cofactor Menin are already undergoing clinical trials for the treatment of hematological diseases [85,90], with the promise of a novel treatment for BCP-ALL in the near future. This evidence concerns the gene DOT1L and hematologic disorder.